Identification | More | [Name]
Loxoprofen | [CAS]
68767-14-6 | [Synonyms]
OLOXO LOXOPROFEN IOXOPROFEN Loxoprofen USP Loxoprofen See L472900 Loxoprofen (base and/or unspecified salts) 2-[p-(2-Oxocyclopentylmethyl)phenyl]propionic acid 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid 2-[4-(2-OXO-CYCLOPENTYLMETHYL)-PHENYL]-PROPIONIC ACID 2-[4-[(2-ketocyclopentyl)methyl]phenyl]propionic acid A-METHYL-4-[(2-OXOCYCLOPENTYL)METHYL]BENZENEACETIC ACID α-methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid 2-[4-[(2-Oxocyclopentan-1-yl)methyl]phenyl]propionic acid Benzeneacetic acid, a-Methyl-4-[(2-oxocyclopentyl)Methyl]- ALPHA-METHYL-4-[(2-OXOCYCLOPENTYL)METHYL]BENZENEACETIC ACID Benzeneacetic acid, a-methyl-4-[(2-oxocyclopentyl)methyl]-(9CI) α-Methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid, Koloxo | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C15H18O3 | [MDL Number]
MFCD00864331 | [Molecular Weight]
246.3 | [MOL File]
68767-14-6.mol |
Chemical Properties | Back Directory | [Melting point ]
108.5-111° | [Boiling point ]
bp0.3 190-195° | [density ]
1.182±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
solid
| [pka]
4.39±0.10(Predicted) | [color ]
White to Off-White | [Merck ]
14,5589 | [InChI]
InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18) | [InChIKey]
YMBXTVYHTMGZDW-UHFFFAOYSA-N | [SMILES]
C(C1CCCC1=O)C1C=CC(C(C)C(=O)O)=CC=1 | [CAS DataBase Reference]
68767-14-6(CAS DataBase Reference) |
Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust . S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [HS Code ]
2918.99.3000 |
Hazard Information | Back Directory | [Uses]
antiinflammatory, analgesic | [Definition]
ChEBI: A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted to its active trans-alcohol metabolite following ora
administration. |
|
|